Accessibility Menu
Evofem Biosciences logo

Evofem Biosciences(OTC) EVFM

Current Price$0.01
Market Cap$1.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-15%
1 Month-6%
Evofem Biosciences last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-24
Evofem Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.49%USD 0.012026-07-17
1 month-6.02%USD 0.012026-06-24
3 month-5.75%USD 0.012026-04-24
Year to date-13.68%USD 0.012025-12-31
1 year-15.46%USD 0.012025-07-24
3 year-98.36%USD 0.502023-07-25
5 year-100%USD 1,669.692021-07-23
Since inception-100%USD 22,725.552018-01-18

Evofem Biosciences Financials at a Glance

Market Cap

$1.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$20.24M

Net Income (TTM)

-$6.05M

EPS (TTM)

-$0.05

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

0.42 (Low)

Price

$0.01

Volume

77,083

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.02

Estimated Earnings Date

Aug 19, 2026

EVFM News

Foolcom-Featured.png

Evofem Revenue Jumps 16 Percent in Q2

Motley Fool Markets TeamAug 14, 2025
GettyImages-459898185

Why Evofem Biosciences Stock Is Falling Today

Prosper Junior BakinyMar 5, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evofem Biosciences

Evofem helps women manage reproductive health with non-hormonal products. Its main offerings prevent pregnancy and treat common infections. These products give women more choices for contraception and infection care.

What’s in the Medicine Cabinet? (Products and Services)

  • PHEXXI vaginal gel: Non-hormonal, prescription gel for pregnancy prevention; primary U.S. product prior to July 2024.
  • SOLOSEC oral granules: Single-dose oral treatment for bacterial vaginosis and trichomoniasis; added in July 2024.
  • EVO100 gel (in development): Antimicrobial gel aiming to prevent chlamydia and gonorrhea transmission in women.
  • International licensing: PHEXXI and SOLOSEC licensed for Middle East and North Africa; PHEXXI approved in Nigeria.

Growth Spurts and Global Steps

  • Acquired global rights to SOLOSEC in July 2024; re-launched November 2024.
  • Signed licensing deal with Pharma 1 Drug Store for Middle East and North Africa in 2024.
  • PHEXXI approved in Nigeria (2022); regulatory filings in UAE, Mexico, Ethiopia, and Ghana ongoing.
  • Partnered with Windtree Therapeutics in 2025 to reduce PHEXXI manufacturing costs.

Why Evofem Isn’t Just Another Biotech

Evofem focuses on non-hormonal and single-dose therapies, offering alternatives to traditional women’s health products. Its lean team and direct sales approach target OB/GYNs and telehealth channels. International licensing and supply partnerships help expand reach and manage costs.

Five Things You Need to Know

  • Q2 2025 net product sales were $4.8 million, up 16% year-over-year.
  • Six-month net product sales fell 27% to $5.7 million as of June 2025.
  • Q2 2025 net loss was $1.8 million, compared to $1.4 million net income in Q2 2024.
  • Three largest customers made up 80% of Q2 2025 gross product sales.
  • Cash and cash equivalents were $0.7 million (all restricted) as of June 30, 2025.

Bottom Line

Evofem has expanded its women’s health portfolio and global reach through acquisitions and partnerships. The company faces significant financial and operational challenges as it seeks stability.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

29

CEO

Saundra L. Pelletier

Website

www.evofem.com

Headquarters

San Diego, CA 92130, US

EVFM Financials

Key Financial Metrics (TTM)

Gross Margin

74.13%

Operating Margin

-17.08%

Net Income Margin

-29.90%

Return on Equity

8.58%

Return on Capital

N/A

Return on Assets

-81.30%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

-2.21%

Stock Overview

Market Cap

$1.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

132.53M

Volume

77.08K

Avg. Volume

297.22K

Financials (TTM)

Gross Profit

$15.00M

Operating Income

-$3.46M

EBITDA

-$2.95M

Operating Cash Flow

-$251.00K

Capital Expenditure

-$7.00K

Free Cash Flow

-$258.00K

Cash & ST Invst.

$2.38M

Total Debt

$52.46M

Evofem Biosciences Performance Analysis

Evofem Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 16,837,000104.2%
20232023-12-31USD 18,218,0008.2%
20242024-12-31USD 19,363,0006.3%
20252025-12-31USD 20,183,0004.2%
Evofem Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30471.0%
Q32025-09-302.6%
Q42025-12-3193.1%
Q12026-03-31-90.6%
Evofem Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -167.42-94.3%
20232023-12-31USD 0.05N/A
20242024-12-31USD -0.12N/A
20252025-12-31USD 0.00N/A
Evofem Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-7800.0%
Q32025-09-309.1%
Q42025-12-31135.7%
Q12026-03-31-924.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$899.00K

+6.4%

Gross Profit

$414.00K

-13.8%

Gross Margin

46.05%

N/A

Market Cap

$1.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$37.47K

N/A

Employees

29

N/A

Net Income

-$5.49M

-673.7%

EBITDA

-$4.46M

-901.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.38M

+976.5%

Total Debt

$52.46M

+14.7%

Accounts Receivable

$560.00K

-51.3%

Inventory

$1.89M

-16.5%

Long Term Debt

$27.00K

+440.0%

Short Term Debt

$52.43M

+14.7%

Return on Assets

-81.30%

N/A

Return on Invested Capital

4.85%

N/A

Free Cash Flow

$2.30M

+310.5%

Operating Cash Flow

$2.30M

+310.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BPTHBio-Path Holdings, Inc.
$0.04+0.00%
MRZMMarizyme, Inc.
$0.00+0.00%
ISCOInternational Stem Cell Corporation
$0.31+10.71%
CAIHFChia Tai Enterprises International Limited
$0.28+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About EVFM

What is the current price of Evofem Biosciences?

Evofem Biosciences is trading at $0.01 per share.

What is the 52-week range for Evofem Biosciences?

Over the past 52 weeks, Evofem Biosciences has traded between $0.00 and $0.02.

How much debt does Evofem Biosciences have?

As of the most recent reporting period, Evofem Biosciences reported total debt of $52.46M.

How much cash does Evofem Biosciences have on hand?

Evofem Biosciences reported $2.38M in cash and cash equivalents in its most recent financial results.

What is Evofem Biosciences’s dividend yield?

Evofem Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services